The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer

Science Signaling

Volumn 9, Issue 448, 2016, Pages

  Antony, Jane ^a,b,c   Tan, Tuan Zea ^a   Kelly, Zoe ^c   Low, Jeffrey ^d   Choolani, Mahesh ^d   Recchi, Chiara ^c   Gabra, Hani ^c   Thiery, Jean Paul ^a,e,f   Huang, Ruby Yun Ju ^a,d,e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH ARREST SPECIFIC PROTEIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN AXL; PROTEIN TYROSINE KINASE; R 428; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR SLUG; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; FUSED ALICYCLIC AROMATIC COMPOUND; GROWTH ARREST-SPECIFIC PROTEIN 6; ONCOPROTEIN; R428 COMPOUND; SIGNAL PEPTIDE; TRIAZOLE DERIVATIVE;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CARCINOGENESIS; CELL MOTILITY; CELL PROLIFERATION; CHORIOALLANTOIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE SILENCING; MESENCHYME; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; CHICK EMBRYO; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; MAPK SIGNALING; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BENZOCYCLOHEPTENES; CELL LINE, TUMOR; CELL MOVEMENT; CHICK EMBRYO; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; MICE; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84990212767     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aaf8175     Document Type: Article

References (56)

1. R. W. Tothill, A. V. Tinker, J. George, R. Brown, S. B. Fox, S. Lade, D. S. Johnson, M. K. Trivett, D. Etemadmoghadam, B. Locandro, N. Traficante, S. Fereday, J. A. Hung, Y.-E. Chiew, I. Haviv; Australian Ovarian Cancer Study Group, D. Gertig, A. deFazio, D. D. L. Bowtell, Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198-5208 (2008).
2. Cancer Genome Atlas Research Network, Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
3. T. Z. Tan, Q. H. Miow, R. Y.-J. Huang, M. K. Wong, J. Ye, J. A. Lau, M. C. Wu, L. H. Bin Abdul Hadi, R. Soong, M. Choolani, B. Davidson, J. M. Nesland, L.-Z. Wang, N. Matsumura, M. Mandai, I. Konishi, B.-C. Goh, J. T. Chang, J. P. Thiery, S. Mori, Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol. Med. 5, 983-998 (2013).
4. A. Helland, M. S. Anglesio, J. George, P. A. Cowin, C. N. Johnstone, C. M. House, K. E. Sheppard, D. Etemadmoghadam, N. Melnyk, A. K. Rustgi, W. A. Phillips, H. Johnsen, R. Holm, G. B. Kristensen, M. J. Birrer; Australian Ovarian Cancer Study Group, R. B. Pearson, A.-L. Børresen-Dale, D. G. Huntsman, A. deFazio, C. J. Creighton, G. K. Smyth, D. D. L. Bowtell, Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLOS ONE 6, e18064 (2011).
5. M. Asad, M. K. Wong, T. Z. Tan, M. Choolani, J. Low, S. Mori, D. Virshup, J. P. Thiery, R.Y.-J. Huang, FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway. Cell Death Dis. 5, e1346 (2014).
6. J. P. Thiery, H. Acloque, R. Y. J. Huang, M. A. Nieto, Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890 (2009).
7. V. Y. Chung, T. Z. Tan, M. Tan, M. K. Wong, K. T. Kuay, Z. Yang, J. Ye, J. Muller, C. M. Koh, E. Guccione, J. P. Thiery, R. Y.-J. Huang, GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification. Sci. Rep. 6, 19943 (2016).
8. R. M. A. Linger, A. K. Keating, H. S. Earp, D. K. Graham, TAM receptor tyrosine kinases: Biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res. 100, 35-83 (2008).
9. S. Goruppi, E. Ruaro, C. Schneider, Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene 12, 471-480 (1996).
10. C. Gjerdrum, C. Tiron, T. Høiby, I. Stefansson, H. Haugen, T. Sandal, K. Collett, S. Li, E. McCormack, B. T. Gjertsen, D. R. Micklem, L. A. Akslen, C. Glackin, J. B. Lorens, Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc. Natl. Acad. Sci. U.S.A. 107, 1124-1129 (2010).
11. M. Ishikawa, M. Sonobe, E. Nakayama, M. Kobayashi, R. Kikuchi, J. Kitamura, N. Imamura, H. Date, Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients. Ann. Surg. Oncol. 20 (Suppl. 3), S467-S476 (2013).
12. S. J. Holland, A. Pan, C. Franci, Y. Hu, B. Chang, W. Li, M. Duan, A. Torneros, J. Yu, T. J. Heckrodt, J. Zhang, P. Ding, A. Apatira, J. Chua, R. Brandt, P. Pine, D. Goff, R. Singh, D. G. Payan, Y. Hitoshi, R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 70, 1544-1554 (2010).
13. X. Song, H. Wang, C. D. Logsdon, A. Rashid, J. B. Fleming, J. L. Abbruzzese, H. F. Gomez, D. B. Evans, H. Wang, Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 117, 734-743 (2011).
14. Z. Zhang, J. C. Lee, L. Lin, V. Olivas, V. Au, T. LaFramboise, M. Abdel-Rahman, X. Wang, A. D. Levine, J. K. Rho, Y. J. Choi, C.-M. Choi, S.-W. Kim, S. J. Jang, Y. S. Park, W. S. Kim, D. H. Lee, J.-S. Lee, V. A. Miller, M. Arcila, M. Ladanyi, P. Moonsamy, C. Sawyers, T. J. Boggon, P. C. Ma, C. Costa, M. Taron, R. Rosell, B. Halmos, T. G. Bivona, Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44, 852-860 (2012).
15. L. A. Byers, L. Diao, J. Wang, P. Saintigny, L. Girard, M. Peyton, L. Shen, Y. Fan, U. Giri, P. K. Tumula, M. B. Nilsson, J. Gudikote, H. Tran, R. J. G. Cardnell, D. J. Bearss, S. L. Warner, J. M. Foulks, S. B. Kanner, V. Gandhi, N. Krett, S. T. Rosen, E. S. Kim, R. S. Herbst, G. R. Blumenschein, J. J. Lee, S. M. Lippman, K. K. Ang, G. B. Mills, W. K. Hong, J. N. Weinstein, I. I. Wistuba, K. R. Coombes, J. D. Minna, J. V. Heymach, An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279-290 (2013).
16. M. Elkabets, E. Pazarentzos, D. Juric, Q. Sheng, R. A. Pelossof, S. Brook, A. O. Benzaken, J. Rodon, N. Morse, J. J. Yan, M. Liu, R. Das, Y. Chen, A. Tam, H. Wang, J. Liang, J. M. Gurski, D. A. Kerr, R. Rosell, C. Teixidó, A. Huang, R. A. Ghossein, N. Rosen, T. G. Bivona, M. Scaltriti, J. Baselga, AXL mediates resistance to PI3Ka inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell 27, 533-546 (2015).
17. D. K. Graham, D. DeRyckere, K. D. Davies, H. S. Earp, The TAM family: Phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer. Nat. Rev. Cancer 14, 769-785 (2014).
18. E. B. Rankin, K. C. Fuh, T. E. Taylor, A. J. Krieg, M. Musser, J. Yuan, K. Wei, C. J. Kuo, T. A. Longacre, A. J. Giaccia, AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res. 70, 7570-7579 (2010).
19. C. Sotiriou, L. Pusztai, Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790-800 (2009).
20. D. Yang, Y. Sun, L. Hu, H. Zheng, P. Ji, C. V. Pecot, Y. Zhao, S. Reynolds, H. Cheng, R. Rupaimoole, D. Cogdell, M. Nykter, R. Broaddus, C. Rodriguez-Aguayo, G. Lopez-Berestein, J. Liu, I. Shmulevich, A. K. Sood, K. Chen, W. Zhang, Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 23, 186-199 (2013).
21. H. S. Leong, L. Galletta, D. Etemadmoghadam, J. George; Australian Ovarian Cancer Study, M. Köbel, S. J. Ramus, D. Bowtell, Efficient molecular subtype classification of high-grade serous ovarian cancer. J. Pathol. 236, 272-277 (2015).
22. R. Y.-J. Huang, M. K. Wong, T. Z. Tan, K. T. Kuay, A. H. C. Ng, V. Y. Chung, Y.-S. Chu, N. Matsumura, H.-C. Lai, Y. F. Lee, W.-J. Sim, C. Chai, E. Pietschmann, S. Mori, J. J. H. Low, M. Choolani, J. P. Thiery, An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis. 4, e915 (2013).
23. C. J. Marshall, Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179-185 (1995).
24. B. N. Kholodenko, J. F. Hancock, W. Kolch, Signalling ballet in space and time. Nat. Rev. Mol. Cell Biol. 11, 414-426 (2010).
25. T. Sawabu, H. Seno, T. Kawashima, A. Fukuda, Y. Uenoyama, M. Kawada, N. Kanda, A. Sekikawa, H. Fukui, M. Yanagita, H. Yoshibayashi, S. Satoh, Y. Sakai, T. Nakano, T. Chiba, Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Mol. Carcinog. 46, 155-164 (2007).
26. K. Rea, P. Pinciroli, M. Sensi, F. Alciato, B. Bisaro, L. Lozneanu, F. Raspagliesi, F. Centritto, S. Cabodi, P. Defilippi, G. C. Avanzi, S. Canevari, A. Tomassetti, Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome. Oncotarget 6, 30859-30875 (2015).
27. E. Vial, C. J. Marshall, Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. J. Cell Sci. 116, 4957-4963 (2003).
28. L. Bakiri, S. Macho-Maschler, I. Custic, J. Niemiec, A. Guío-Carrión, S. C. Hasenfuss, A. Eger, M. Müller, H. Beug, E. F. Wagner, Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expression. Cell Death Differ. 22, 336-350 (2015).
29. K.-N. Chua, W.-J. Sim, V. Racine, S.-Y. Lee, B. C. Goh, J. P. Thiery, A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma. PLOS ONE 7, e33183 (2012).
30. E. J. Morris, S. Jha, C. R. Restaino, P. Dayananth, H. Zhu, A. Cooper, D. Carr, Y. Deng, W. Jin, S. Black, B. Long, J. Liu, E. Dinunzio, W. Windsor, R. Zhang, S. Zhao, M. H. Angagaw, E. M. Pinheiro, J. Desai, L. Xiao, G. Shipps, A. Hruza, J. Wang, J. Kelly, S. Paliwal, X. Gao, B. S. Babu, L. Zhu, P. Daublain, L. Zhang, B. A. Lutterbach, M. R. Pelletier, U. Philippar, P. Siliphaivanh, D. Witter, P. Kirschmeier, W. R. Bishop, D. Hicklin, D. G. Gilliland, L. Jayaraman, L. Zawel, S. Fawell, A. A. Samatar, Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 3, 742-750 (2013).
31. J. Yang, S. A. Mani, J. L. Donaher, S. Ramaswamy, R. A. Itzykson, C. Come, P. Savagner, I. Gitelman, A. Richardson, R. A. Weinberg, Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939 (2004).
32. A. S. Meyer, A. J. M. Zweemer, D. A. Lauffenburger, The AXL receptor is a sensor of ligand spatial heterogeneity. Cell Syst. 1, 25-36 (2015).
33. K. Simons, E. Ikonen, Functional rafts in cell membranes. Nature 387, 569-572 (1997).
34. N. L. G. Sieben, J. Oosting, A. M. Flanagan, J. Prat, G. M. J. M. Roemen, S. M. Kolkman-Uljee, R. van Eijk, C. J. Cornelisse, G. J. Fleuren, M. van Engeland, Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J. Clin. Oncol. 23, 7257-7264 (2005).
35. T. Z. Tan, Q. H. Miow, Y. Miki, T. Noda, S. Mori, R. Y.-J. Huang, J. P. Thiery, Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol. Med. 6, 1279-1293 (2014).
36. A. S. Brodsky, A. Fischer, D. H. Miller, S. Vang, S. MacLaughlan, H.-T. Wu, J. Yu, M. Steinhoff, C. Collins, P. J. S. Smith, B. J. Raphael, L. Brard, Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease. PLOS ONE 9, e94476 (2014).
37. S. Marchini, R. Fruscio, L. Clivio, L. Beltrame, L. Porcu, I. Fuso Nerini, D. Cavalieri, G. Chiorino, G. Cattoretti, C. Mangioni, R. Milani, V. Torri, C. Romualdi, A. Zambelli, M. Romano, M. Signorelli, S. di Giandomenico, M. D'Incalci, Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur. J. Cancer 49, 520-530 (2013).
38. T. Z. Tan, H. Yang, J. Ye, J. Low, M. Choolani, D. S. P. Tan, J.-P. Thiery, R. Y.-J. Huang, CSIOVDB: A microarray gene expression database of epithelial ovarian cancer subtype. Oncotarget 6, 43843-43852 (2015).
39. J. P. O'Bryan, R. A. Frye, P. C. Cogswell, A. Neubauer, B. Kitch, C. Prokop, R. Espinosa III, M. M. Le Beau, H. S. Earp, E. T. Liu, axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol. Cell. Biol. 11, 5016-5031 (1991).
40. T. S. Gujral, R. L. Karp, A. Finski, M. Chan, P. E. Schwartz, G. MacBeath, P. Sorger, Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Oncogene 32, 3470-3476 (2013).
41. L. Liu, J. Greger, H. Shi, Y. Liu, J. Greshock, R. Annan, W. Halsey, G. M. Sathe, A.-M. Martin, T. M. Gilmer, Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL. Cancer Res. 69, 6871-6878 (2009).
42. A. S. Meyer, M. A. Miller, F. B. Gertler, D. A. Lauffenburger, The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci. Signal. 6, ra66 (2013).
43. L. Cerchia, C. L. Esposito, S. Camorani, A. Rienzo, L. Stasio, L. Insabato, A. Affuso, V. de Franciscis, Targeting Axl with an high-affinity inhibitory aptamer. Mol. Ther. 20, 2291-2303 (2012).
44. X. Ye, Y. Li, S. Stawicki, S. Couto, J. Eastham-Anderson, D. Kallop, R. Weimer, Y. Wu, L. Pei, An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29, 5254-5264 (2010).
45. W. Leconet, C. Larbouret, T. Chardès, G. Thomas, M. Neiveyans, M. Busson, M. Jarlier, N. Radosevic-Robin, M. Pugnière, F. Bernex, F. Penault-Llorca, J.-M. Pasquet, A. Pèlegrin, B. Robert, Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene 33, 5405-5414 (2014).
46. E. Vial, E. Sahai, C J. Marshall, ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4, 67-79 (2003).
47. H.-J. Lee, Y.-M. Jeng, Y.-L. Chen, L. Chung, R.-H. Yuan, Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma. Carcinogenesis 35, 769-775 (2014).
48. S. Shin, J. Blenis, ERK2/Fra1/ZEB pathway induces epithelial-to-mesenchymal transition. Cell Cycle 9, 2483-2484 (2010).
49. C. Wilson, X. Ye, T. Pham, E. Lin, S. Chan, E. McNamara, R. M. Neve, L. Belmont, H. Koeppen, R. L. Yauch, A. Ashkenazi, J. Settleman, AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. Cancer Res. 74, 5878-5890 (2014).
50. F. Wu, J. Li, C. Jang, J. Wang, J. Xiong, The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma. Int. J. Clin. Exp. Pathol. 7, 6653-6661 (2014).
51. J. K. Rho, Y. J. Choi, S. Y. Kim, T. W. Kim, E. K. Choi, S.-J. Yoon, B. M. Park, E. Park, J. H. Bae, C.-M. Choi, J. C. Lee, MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res. 74, 253-262 (2014).
52. M. F. Burbridge, C. J. Bossard, C. Saunier, I. Fejes, A. Bruno, S. Léonce, G. Ferry, G. Da Violante, F. Bouzom, V. Cattan, A. Jacquet-Bescond, P. M. Comoglio, B. P. Lockhart, J. A. Boutin, A. Cordi, J.-C. Ortuno, A. Pierré, J. A. Hickman, F. H. Cruzalegui, S. Depil, S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol. Cancer Ther. 12, 1749-1762 (2013).
53. X. Wu, X. Liu, S. Koul, C. Y. Lee, Z. Zhang, B. Halmos, AXL kinase as a novel target for cancer therapy. Oncotarget 5, 9546-9563 (2014).
54. R. A. Okimoto, T. G. Bivona, AXL receptor tyrosine kinase as a therapeutic target in NSCLC. Lung Cancer Targets and Ther. 2015, 27-34 (2015).
55. M. S. Kariolis, Y. R. Miao, D. S. Jones II, S. Kapur, I.I. Mathews, A. J. Giaccia, J. R. Cochran, An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis. Nat. Chem. Biol. 10, 977-983 (2014).
56. D. H. Ausprunk, D. R. Knighton, J. Folkman, Vascularization of normal and neoplastic tissues grafted to the chick chorioallantois. Role of host and preexisting graft blood vessels. Am. J. Pathol. 79, 597-618 (1975).